| There will be no additional appropriated cost to the Department of Public Aid. Assuming rebates for prescriptions paid by Medicaid will continue to be deposited into the Drug Rebate Fund, the only potential impact IDPA could be a reduction of the "Best Price" charged by a manufacturer which could reduce the level of federal rebates. There will be administrative costs associated with operating this program. Either a complicated tracking system will need to be developed and staffed, or an outside entity will need to be hired. Additionally, IDOR will pay all but $1.00 for generic and $4.00 for name brand drug prescriptions. Without knowing the number of rule additions or the rebate agreements negotiated, the additional cost of the legislation could not be defined. |